Enacts the "New York affordable drug manufacturing act" to direct the commissioner of health to enter into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs.
Directs the department of health to report to the legislature on the feasibility of entering into partnerships to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs; makes related provisions.
Requires certain manufacturers of prescription drugs to notify the superintendent of any proposed increase of the wholesale acquisition cost of such prescription drugs.
Requires certain manufacturers of prescription drugs to notify the superintendent of any proposed increase of the wholesale acquisition cost of such prescription drugs.
Relates to reducing the cost of prescription drugs by establishing maximum wholesale drug prices that are the same as the prices in Canada.
Relates to reducing the cost of prescription drugs by establishing maximum wholesale drug prices that are the same as the prices in Canada.
Directs the department of health to create a prescription drug inventory database that contains a list of all drugs designated as being currently in shortage by the federal food and drug administration's drug shortages database, and a list of pharmacies in the state where each such drug is currently in stock.
Relates to access to appropriate drugs at reasonable prices, formulary exceptions, standing prior authorizations and external appeals; to access to retail pharmacies, prescription synchronization, limits on patient drug costs, explanations of benefits and rebates; to prescription drug synchronization; to pharmacy benefit management; and to limits on copayments and drug substitutions.
Increases penalties for the crimes of criminal diversion of prescription medications and prescriptions in the first, second, third and fourth degrees and criminal sale of a prescription.
Enacts the "foreign drug transparency act"; requires the disclosure to a health plan, pharmacy and patient whether a prescription drug was manufactured or compounded in a foreign country; whether the prescription was approved by the federal food and drug administration foreign drug inspection program; requires the date of the last inspection of such prescription drug by the federal food and drug administration foreign drug inspection program; requires certain labelling on such drugs.